Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Venocur Triplex is an oral combination drug indicated for the treatment of chronic venous insufficiency, varicose veins, post-thrombotic syndrome, static edema, peripheral circulatory disorders, thrombophlebitis, and for the prophylaxis of thrombosis and embolism in surgical settings. Its active ingredients are Castanha da Índia (horse chestnut extract), Miroton (likely a trade name or specific formulation component), and Rutosídeo (rutoside/rutin). The drug acts primarily as a venotonic and vasoprotective agent—improving venous tone, reducing capillary permeability and fragility, decreasing edema formation, and enhancing microcirculation. It is classified therapeutically as an anti-inflammatory/antivaricose agent. Clinical studies have shown its use in chronic venous insufficiency rated between CEAP 2–4[5][9]. The medication is typically administered orally after meals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Venocur Triplex.